Edwards Lifesciences Corporation $EW Shares Sold by DekaBank Deutsche Girozentrale

Key Points

• DekaBank Deutsche Girozentrale decreased its stake in Edwards Lifesciences Corporation by 10.9%, now holding 1,747,168 shares worth approximately $137 million.
• Several institutional investors, including Jennison Associates and UBS Asset Management, increased their positions, indicating a growing interest in Edwards Lifesciences.
• Analysts have raised price targets for Edwards Lifesciences, with the consensus target now set at $87.06, reflecting positive sentiment despite recent insider selling.

DekaBank Deutsche Girozentrale reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,747,168 shares of the medical research company's stock after selling 214,041 shares during the period. DekaBank Deutsche Girozentrale owned about 0.30% of Edwards Lifesciences worth $137,048,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock valued at $491,673,000 after buying an additional 264,311 shares in the last quarter. Nuveen LLC purchased a new stake in Edwards Lifesciences during the first quarter valued at about $330,881,000. Invesco Ltd. lifted its stake in Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock valued at $310,773,000 after buying an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Edwards Lifesciences by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company's stock valued at $287,140,000 after buying an additional 198,882 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EW. Piper Sandler increased their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $87.06.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $75.31 on Tuesday. The firm has a market cap of $44.22 billion, a PE ratio of 10.84, a PEG ratio of 3.58 and a beta of 1.05. The firm's 50 day moving average price is $77.48 and its 200 day moving average price is $76.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the company posted $0.70 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.